Your session is about to expire
← Back to Search
Irinotecan + Temozolomide for Ewing Sarcoma
Study Summary
This trial is studying the use of two chemotherapy drugs, irinotecan and temozolomide, in patients with newly diagnosed Ewing sarcoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I was diagnosed with my condition between the ages of 1 and 40.I have been newly diagnosed with Ewing sarcoma and have not received any treatment.My kidney function tests are normal.I have not had chemotherapy or radiotherapy, except for emergency treatment.My liver tests are within the required limits.My heart functions well, as confirmed by heart imaging tests.My kidney function is within the normal range for my age.My liver functions are within the required limits.My blood tests show normal white cell and platelet counts.My heart is functioning well, as confirmed by heart tests.I am willing to use birth control if I can have children.My blood tests show normal white blood cell and platelet counts.
- Group 1: Patients with localized disease
- Group 2: Patients with metastatic disease
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the trial recruiting participants below the age of eighteen?
"This medical experiment is seeking individuals between one year old and forty years of age."
Who is capable of participating in this medical research?
"Currently, 93 individuals aged 1 to 40 with newly-diagnosed Ewing sarcoma are being sought after for this clinical trial. To qualify, they must have a creatinine level within the listed parameters; their absolute neutrophil count needs to be at least 1000/Kmcl and platelet count 100000/kmcl or more; total bilirubin should not outrun upper limit of normal (ULN) by 1.5 times; Alanine transaminase (AST) and aspartate aminotransferase (ALT) need to remain below ULN twice unless there is significant hepatic"
How many individuals are participating in this research endeavor?
"Affirmative. According to information presented on clinicaltrials.gov, this experiment is actively searching for volunteers and has been since May 1st 2013. The trial is currently welcoming 93 people at 7 different medical sites with the last update having taken place June 1st 2022."
Has the Food and Drug Administration given its stamp of approval to Irinotecan?
"Irinotecan's safety rating is 2, as this Phase 2 trial has data that suggests its safety but no evidence of efficacy."
Is the recruitment of participants still open for this trial?
"Affirmative. According to clinicaltrials.gov, this research is presently enrolling participants who meet the inclusion criteria. First posted on May 1st 2013 and last updated June 1st 2022, it seeks 93 patients from 7 different sites for evaluation."
How many geographical sites is the study conducted in?
"The trial is currently running in 7 locations, such as Memorial Sloan Kettering Bergen in Montvale and Memorial Sloan Kettering Westchester in Harrison. Additionally there are 4 other sites for this study, including the facility located at Commack."
Can you provide information about prior Irinotecan trials?
"Irinotecan's first known clinical trial was launched at City of Hope Comprehensive Cancer Center in 1997. To date, there have been 2601 completed studies and 1516 are currently recruiting participants. Many research sites for this medication are located in Montvale, New jersey."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger